Cargando…
Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
BACKGROUND: This study assessed the prognostic value of HE4 marker measurements at various stages of first-line chemotherapy for ovarian cancer. METHODS: The study consisted of 90 ovarian cancer patients, including 48 women undergoing primary surgical treatment and 42 patients qualified for neoadjuv...
Autores principales: | Chudecka-Głaz, Anita, Cymbaluk-Płoska, Aneta, Wężowska, Małgorzata, Menkiszak, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870956/ https://www.ncbi.nlm.nih.gov/pubmed/29584739 http://dx.doi.org/10.1371/journal.pone.0194270 |
Ejemplares similares
-
Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016) -
HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases
por: Chudecka-Głaz, Anita, et al.
Publicado: (2017) -
Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016) -
Suitability assessment of baseline concentration of MMP3, TIMP3, HE4 and CA125 in the serum of patients with ovarian cancer
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2018) -
Ectopic pregnancy treatment by combination therapy
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2016)